Piper Jaffray analyst Matt O'Brien raised his price target for Abiomed to $300 from $220 after the company reported fiscal Q3 results and 2018 guidance in line with its preannouncement. The analyst believes the highlight of the quarter was emergent utilization coming in at an impressive 43%. O'Brien also notes that RP accounted for 5% of sales, which he views as a strong positive that not only is Impella RP being placed at more and more sites but utilization at existing sites is accelerating as well. Lastly, he was encouraged by Abiomed being well ahead of schedule in Japan. The analyst reiterates an Overweight rating on the shares.